The stock of AngioDynamics, Inc. (NASDAQ:ANGO) is a huge mover today! About 509,926 shares traded hands or 165.59% up from the average. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 44.68% since March 7, 2016 and is uptrending. It has outperformed by 37.08% the S&P500.
The move comes after 9 months positive chart setup for the $638.74 million company. It was reported on Oct, 10 by Barchart.com. We have $21.06 PT which if reached, will make NASDAQ:ANGO worth $140.52M more.
Analysts await AngioDynamics, Inc. (NASDAQ:ANGO) to report earnings on October, 13. They expect $0.13 EPS, up 18.18% or $0.02 from last year’s $0.11 per share. ANGO’s profit will be $4.81 million for 33.19 P/E if the $0.13 EPS becomes a reality. After $0.19 actual EPS reported by AngioDynamics, Inc. for the previous quarter, Wall Street now forecasts -31.58% negative EPS growth.
AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage
Out of 5 analysts covering AngioDynamics (NASDAQ:ANGO), 1 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 20% are positive. AngioDynamics has been the topic of 7 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Canaccord Genuity maintained AngioDynamics, Inc. (NASDAQ:ANGO) rating on Friday, January 8. Canaccord Genuity has “Buy” rating and $14.5 price target. Zacks upgraded the shares of ANGO in a report on Monday, August 31 to “Sell” rating. The firm has “Mkt Perform” rating given on Tuesday, November 10 by Raymond James. On Wednesday, September 23 the stock rating was initiated by Sidoti with “Neutral”. The stock has “Hold” rating given by Canaccord Genuity on Tuesday, April 5. As per Friday, July 24, the company rating was initiated by KeyBanc Capital Markets. The stock has “Neutral” rating given by Piper Jaffray on Friday, April 8.
According to Zacks Investment Research, “AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company’s diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products.”
Insitutional Activity: The institutional sentiment increased to 1.87 in 2016 Q2. Its up 0.50, from 1.37 in 2016Q1. The ratio improved, as 11 funds sold all AngioDynamics, Inc. shares owned while 20 reduced positions. 10 funds bought stakes while 48 increased positions. They now own 24.22 million shares or 1.02% less from 24.47 million shares in 2016Q1.
Jacobs Levy Equity Management last reported 0.01% of its portfolio in the stock. Tower Rech Capital Ltd Liability Co (Trc) reported 482 shares or 0% of all its holdings. Oxford Asset Mngmt has 0.04% invested in the company for 60,717 shares. Blackrock Institutional Co Na last reported 959,777 shares in the company. Credit Suisse Ag has 0% invested in the company for 56,447 shares. Voya Invest Ltd Liability holds 0% or 13,527 shares in its portfolio. The Hawaii-based C M Bidwell has invested 0.03% in AngioDynamics, Inc. (NASDAQ:ANGO). Secor Advisors Ltd Partnership, a New York-based fund reported 36,017 shares. Moreover, State Of New Jersey Common Pension Fund D has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 65,000 shares. Moreover, Texas Permanent School Fund has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 20,222 shares. Swiss National Bank & Trust has 0% invested in the company for 48,900 shares. Moreover, Morgan Stanley has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 59,976 shares. Moreover, Bnp Paribas Arbitrage Sa has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 8,174 shares. Bancorp Of New York Mellon Corp last reported 427,529 shares in the company. Wells Fargo Co Mn owns 626,223 shares or 0% of their US portfolio.
Insider Transactions: Since April 21, 2016, the stock had 0 insider purchases, and 4 insider sales for $65.86 million net activity. 12,940 shares were sold by Trowbridge Stephen A, worth $159,184 on Thursday, April 21. Another trade for 2.25M shares valued at $32.90M was made by Burgstahler David F on Friday, August 5. Avista Capital Partners GP – LLC also sold $32.76 million worth of AngioDynamics, Inc. (NASDAQ:ANGO) on Friday, August 5. Greiner Charles R sold $43,183 worth of AngioDynamics, Inc. (NASDAQ:ANGO) on Friday, May 6.
More recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: Prnewswire.com which released: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating …” on September 19, 2016. Also Nasdaq.com published the news titled: “Earnings Reaction History: AngioDynamics Inc., 75.0% Follow-Through Indicator …” on October 05, 2016. Blogs.Wsj.com‘s news article titled: “Stocks to Watch: Eli Lilly, AngioDynamics, AZZ” with publication date: October 05, 2016 was also an interesting one.
ANGO Company Profile
AngioDynamics, Inc., incorporated on July 30, 1992, designs, makes and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.